Statistics from Altmetric.com
ABSTRACT FROM: Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry 2015;76:1085–90.
What is already known on this topic?
Depot antipsychotics may increase adherence to medication, reducing recurrence and rehospitalisation in schizophrenia.1 Aripiprazole lauroxil, a novel lipid ester prodrug of aripiprazole, is a long-acting injection (LAI) administered intramuscularly. After injection, it is metabolised by esterases to N-hydroxymethyl aripiprazole and then hydrolysed to aripiprazole. The available doses are 441, 662 and 882 mg every 4–6 weeks, corresponding to oral aripiprazole doses of 10, 15 and 20 mg/day or higher, respectively (those features add some flexibility to previously available formulations of aripiprazole LAI). Results from phase I studies about aripiprazole lauroxil …
Competing interests YT has received grant funding from Grant-in-Aid for Young Scientists (B) from Japan Society for the Promotion of Science and speaker's honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma and Janssen Pharmaceutical, within the past 3 years. AS is or has been consultant/speaker for Abbott, AbbVie, Angelini, Astra Zeneca, Clinical Data, Boehringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polipharma, Sanofi and Servier.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.